Published On: Wed, Oct 19th, 2016

Broker Changes For KaloBios Pharmaceuticals, Inc. (KBIO)

Recently stock market analysts have updated their consensus ratings on shares of KaloBios Pharmaceuticals, Inc. (KBIO).

Most recent broker ratings

11/19/2015 – KaloBios Pharmaceuticals, Inc. had its “hold” rating reiterated by analysts at Needham & Company.

05/15/2015 – KaloBios Pharmaceuticals, Inc. was upgraded to “buy” by analysts at Zacks. They now have a USD 0.5 price target on the stock.

01/07/2015 – KaloBios Pharmaceuticals, Inc. was downgraded to “market perform” by analysts at JMP Securities.

KaloBios Pharmaceuticals, Inc. has a 50 day moving average of 3.42 and a 200 day moving average of 4.09. The stock’s market capitalization is 51.42M, it has a 52-week low of 0.44 and a 52-week high of 45.82.

The share price of the company (KBIO) was up +7.48% during the last trading session, with a high of 3.60 and the volume of KaloBios Pharmaceuticals, Inc. shares traded was 6216.

KaloBios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on developing medicines for patients with neglected and rare diseases, with an ancillary focus on pediatric conditions. The Company’s product candidate is benznidazole for the treatment of Chagas disease, a parasitic illness that can lead to long-term heart, intestinal and neurological problems. It is engaged in developing monoclonal antibodies, lenzilumab, for the treatment of chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia both of which are rare hematologic cancers. It is exploring development of another of its monoclonal antibodies, ifabotuzumab, for the treatment of rare solid and hematologic cancers. Its KB001-A, is a Humaneered, PEGylated, anti-PcrV modified antibody fragment (Fab) antibody developed for the prevention and treatment of Pseudomonas aeruginosa (Pa), infections in mechanically ventilated patients and cystic fibrosis (CF), patients with chronic Pa lung infections.